Novartis signs $7.8 billion Abogen RNA deal
Novartis (NYSE:NVS) signed a licensing and option agreement with privately held Abogen Biosciences worth up to about $7.8 billion for ABO2203 and other potential RNA-based programs.
Every story in this section, newest first — page 38 of 373.
Novartis (NYSE:NVS) signed a licensing and option agreement with privately held Abogen Biosciences worth up to about $7.8 billion for ABO2203 and other potential RNA-based programs.
Tesla (NASDAQ:TSLA) reported third-quarter 2026 vehicle deliveries of 486,532 alongside total production of 464,391 vehicles.
Satellogic (NASDAQ:SATL) successfully launched its first Merlin satellite and three NewSat spacecraft into low-Earth orbit on October 1, 2026.
Surrozen (NASDAQ:SRZN) received U.S. FDA clearance of its investigational new drug application for SZN-8141, enabling clinical development for diabetic macular edema.
Rivian Automotive (NASDAQ:RIVN) announced its production and delivery totals for the quarter ending September 30, 2026.
Ruanyun Edai Technology (NASDAQ:RYET) expects preliminary unaudited first-half fiscal 2027 revenue of approximately US$9.3 million to US$9.5 million.
Teva (NYSE:TEVA) announced new efficacy and safety analyses of ecopipam, its investigational treatment for pediatric patients with Tourette syndrome.
Taylor Devices (NASDAQ:TAYD) reported lower fiscal 2027 first-quarter sales of $7,300,239 alongside a decline in net earnings.
Integra LifeSciences (NASDAQ:IART) lowered its full-year 2026 revenue guidance to between $1.634 billion and $1.654 billion following a severe flood at its Cincinnati production facility.
Haoxin Holdings (NASDAQ:HXHX) engaged a business broker to evaluate potential logistics acquisitions as part of its North American expansion initiative.
Freeport (NYSE:FCX) reported third-quarter consolidated copper production of approximately 830 million pounds and gold production of 230,000 ounces.
onsemi (NASDAQ:ON) amended its agreement to acquire Synaptics (NASDAQ:SYNA), switching to a $5.7 billion all-cash purchase at $123 per share.
Aura Minerals (NASDAQ:AUGO) signed a definitive agreement to acquire Newco for R$612 million, or approximately US$118 million, bringing mining fleet operations in-house at three Brazilian gold mines.
Embraer (NYSE:EMBJ) delivered 66 total aircraft during the third quarter of 2026.
Alta Equipment Group (NYSE:ALTG) approved a quarterly preferred stock dividend of $625 per share payable on October 30, 2026.
ACCO Brands Corporation (NYSE:ACCO) officially finalized its acquisition of Netherlands-based computer accessories provider Trust.
Ryanair (NASDAQ:RYAAY) reported a 4% year-over-year increase in September traffic to over 20.1 million passengers.
Johnson & Johnson (NYSE:JNJ) announced Phase 3 clinical results showing sustained skin clearance with ICOTYDE for plaque psoriasis.
TNL Mediagene (NASDAQ:TNMG) signed a definitive agreement to sell its Japanese business for $5.5 million to MI Company, an acquisition vehicle backed by an investor group led by CEO Motoko Imada.
Flowco Holdings (NYSE:FLOC) completed its acquisition of Lifting Solutions Energy Services for approximately US$113 million in cash, expanding its artificial lift portfolio and geographic reach.
Nike (NYSE:NKE) shares fell 8.5% to $32.15 premarket after the sportswear company forecast a high-single-digit fiscal 2027 revenue decline following first-quarter sales of $11.21 billion.
Moderna (NASDAQ:MRNA) shares climbed 2.2% to $193.01 premarket after Nasdaq said the vaccine maker will replace Warner Bros. Discovery (NASDAQ:WBD) in the Nasdaq-100 Index on October 9.
Brent crude fell 0.7% to $101.61 a barrel on Friday while West Texas Intermediate dropped 0.9% to $92.02 as traders weighed improving Middle Eastern supply against geopolitical risks.
Venture Global (NYSE:VG) signed a 20-year sales and purchase agreement with ConocoPhillips (NYSE:COP) to supply 1.0 million tonnes of LNG annually beginning in 2030.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy